ClinicalTrialsFinder
RecruitingNCT05567133

Risk Indicators of Sarcoidosis Evolution-Unified Protocol

Development of Clinical Prediction Models for Pulmonary Outcomes in Sarcoidosis

Sponsor

University of California, San Francisco

Enrollment

200 participants

Start Date

Jan 10, 2023

Study Type

OBSERVATIONAL

Conditions

Sarcoidosis, Pulmonary

Summary

The purpose of this study is to develop prediction models that can prognosticate patients with sarcoidosis using clinical data and blood markers that can be obtained during a clinic visit.

Eligibility

Min Age: 19 Years

Inclusion Criteria2

  • Adults with a diagnosis of sarcoidosis over the age of 18
  • Case definition: we will follow the 1999 statement on sarcoidosis published by the American Thoracic Society for diagnosis which includes tissue biopsy confirmation and exclusion of alternative diagnoses including beryllium sensitization/chronic beryllium disease, mycobacterial, viral, and/or fungal infection

Exclusion Criteria5

  • Inability to tolerate study procedures as determined by the investigator
  • Pregnant or breastfeeding
  • Concurrent medical diagnoses that would influence the expression of biomarkers will be considered an exclusion criterion. This includes diseases such as common variable immunodeficiency, HIV infection, or autoimmune diseases
  • Concurrent interstitial lung diseases such as hypersensitivity pneumonitis or idiopathic pulmonary fibrosis
  • Hematocrit (Packed Cell Volume) < 25%

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(2)

University of Maryland

Baltimore, Maryland, United States

UT Southwestern

Dallas, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05567133

Related Trials

Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis

NCT0584175821 locations

Diagnostic Yield of Intranodal Forceps Biopsies in Mediastinal Adenopathy

NCT053744471 location

Feasibility of Semaglutide in Advanced Lung Disease

NCT057460391 location

RCT of Nintedanib in Fibrotic Sarcoidosis

NCT064796031 location

Exploring the Utility of Hyperpolarized 129Xe MRI in Healthy Volunteers and Patients With Lung Disease

NCT034556861 location